FLINT, Mich. – June 28, 2016 – The nation’s largest independent specialty pharmacy will have access to dispense EPCLUSA® (sofosbuvir/velpatasvir) to treat patients with chronic hepatitis C infection.

Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it will be dispensing EPCLUSA® (sofosbuvir/velpatasvir) for the treatment of patients with chronic hepatitis C virus (HCV) infection. EPCLUSA® is a once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir, approved as Sovaldi® in December 2013, and velpatasvir, an investigational pan-genotypic NS5A inhibitor, for the treatment of HCV genotypes 1-6.

To learn more about Diplomat’s hepatitis program, click here.

“HCV is a serious condition that can change a person’s life,” said Gary Kadlec, Diplomat president. “We are excited to offer patients the first effective treatment option for all six genotypes of HCV.”

Hepatitis C is a viral disease that causes inflammation of the liver, which can lead to diminished liver function or liver failure. Some people with chronic HCV may develop cirrhosis, in which liver tissue is replaced by scar tissue, eventually preventing the liver from functioning properly.

According to the Centers for Disease Control and Prevention (CDC), more than 2.7 million Americans have chronic hepatitis C. Up to 75 percent of these individuals might not know they are infected. The CDC recommends everyone born between 1945 and 1965, as well as those with risk factors, be tested for HCV.

EPCLUSA® is manufactured by Gilead Sciences, Inc. Please see full prescribing information for EPCLUSA® at www.gilead.com.

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise. 

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.

###

CONTACT:
Kali Lucas, Public Relations Coordinator
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education and Human Resources
810.768.9863 | grice@diplomat.is

Twitter